Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression
Open Access
- 25 January 2023
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 24 (3) , e117-e121
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung CancerJournal of Thoracic Oncology, 2021
- Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practiceNature Reviews Clinical Oncology, 2020
- Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysisBMC Cancer, 2020
- Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung CancerClinical Cancer Research, 2020
- Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung CancerJAMA Oncology, 2019
- Tracking the Evolution of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing AssaysThe Journal of Molecular Diagnostics, 2017
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancerNature Communications, 2015
- Longitudinal Data Analysis for Discrete and Continuous OutcomesBiometrics, 1986